Recent Quotes (30 days)

You have no recent quotes
chg | %

Shire PLC news

   Watch this stock
Showing stories 1 - 10 of about 110   

Articles published

SHP 5,325.00 +15.00 (0.28%)
price chart
AbbVie-Shire Deal Now In The Hands Of EU Competition Regulators
The decision will effectively decide whether AbbVie will be able to acquire Shire in an attempt to take advantage of tax inversion and to become one of the global leaders in the rare disease management market.
AbbVie Inc.'s $54.5 billion purchase of Shire Plc (SHP) to move...  Mynextfone
EU to decide on $52 billion AbbVie, Shire deal by Oct. 16  Reuters
Related articles »  
AbbVie Said to Weigh More Shire Financing After U.S. Rule
AbbVie Inc. (ABBV) is examining plans to raise additional financing to complete its takeover of Shire Plc (SHP), after U.S.
Related articles »  
Director Deals - Shire PLC (SHP) - Dominic Blakemore, Non Executive Director, received in lieu of fees/salary 98 shares in the company on the 30th September 2014 at a price of 5345.00p.
Related articles »  
Shire PLC Receives Consensus Recommendation of "Buy" from Analysts (LON ...
Shire PLC logo Shire PLC (LON:SHP) has been given a consensus rating of �Buy� by the twenty-five brokerages that are currently covering the stock, AnalystRatingsNetwork.
Panmure Gordon Downgrades Shire PLC to Hold (SHP)  Mideast Time
Shire PLC Given "Market Perform" Rating at Sanford C. Bernstein (SHP)  sleekmoney
Related articles »  
Is The AbbVie-Shire Deal In Trouble?
AbbVie Inc (ABBV) is searching for sources to raise funds for its pending $55 billion acquisition deal of Shire PLC (ADR) (SHPG).
Shire to pay $56.5 million to settle improper marketing probe
(Reuters) - Shire Plc, which is in the process of being acquired by AbbVie Inc, has agreed to pay $56.5 million to resolve allegations of making false claims in the marketing of its ADHD drug Adderall XR and other medicines, the U.S.
Shire to Pay $56.5 Million to Settle False Marketing Claims  Wall Street Journal
Justice Department says Shire will pay $56.5M fine  New Zealand Herald
Related articles »  
Shire's Drug To Put An End To Binge Eating
The FDA accepted Shire PLC (ADR)'s (SHPG) supplemental New Drug Application (sNDA) yesterday, granting a Priority Review for the label expansion of the biopharmaceutical's drug Vyvanse, which is used for treating Binge Eating Disorder (BED) in adults ...
Shire Plc: FDA Accepts Filing With Priority Review Of SNDA For Vyvanse  RTT News
Related articles »  
Shire PLC Downgraded to Hold at Panmure Gordon (SHP)
Panmure Gordon cut shares of Shire PLC (LON:SHP) to a hold rating in a research report sent to investors on Thursday morning.
Shire PLC Rating Reiterated by AlphaValue (SHP)  sleekmoney
AlphaValue Reaffirms "Reduce" Rating for Shire PLC (SHP)  Intercooler
Related articles »  
Shire plc: Form 8.3 - SHIRE PLC
Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
Shire plc: Form 8.3 - AbbVie
(f) Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer?
Form 8.3 - Shire PLC  Business Wire (press release)
Related articles »